Larotrectinib: Additional Ph I data

Data from 7 evaluable patients with advanced solid tumors refractory to standard therapy harboring a Trk gene fusion in an open-label, dose-escalation, U.S. Phase I trial showed that oral larotrectinib led to 6 confirmed partial responses and 1 case of stable disease as measured by RECIST criteria. The trial has enrolled 59 patients with refractory solid tumors to receive once-daily 50, 100 or 200 mg larotrectinib or twice-daily 100, 150 or 200 mg larotrectinib. Data were presented at the European Society for Medical Oncology Asia meeting in Singapore. Loxo has previously reported data from the trial (see BioCentury, May 4, 2015; Aug. 3, 2015; Nov. 16, 2015 & April 25, 2016)...